Xilonix: Interim Phase II data

Interim data from 42 evaluable patients undergoing percutaneous revascularization of the superficial femoral artery in an open-label, U.S. Phase II trial showed that MABp1 plus standard of care (SOC) led to a 58% reduction in the incidence of MACE vs. SOC alone. Additionally, patients treated with MABp1 plus SOC experienced 60% longer vessel patency vs. SOC alone. XBiotech said vessel patency evaluated the ability of MABp1 to reduce restenosis by blocking vascular inflammation after revascularization using balloon angioplasty, atherectomy or stent placement. Adverse events in both groups appeared to be related to underlying disease. ...